Paediatric Burkitt lymphoma patient‐derived xenografts capture disease characteristics over time and are a model for therapy
| Autor: | Simon Bomken, Aengus O'Marcaigh, Gladstone A A Burke, Leila Jahangiri, Liam C. Lee, Suzanne D. Turner, Olivier Giger, Helen J. Blair, Natalie Bell, Sorcha Forde, Tim Malcolm, Lukas Kenner, Owen P. Smith, Jamie D. Matthews, Nina Prokoph |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Tumour heterogeneity Mice 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine MYC Translocation Tumor Cells Cultured medicine Animals Humans Treatment resistance Child Survival rate business.industry Hematology medicine.disease Burkitt Lymphoma Lymphoma Gene Expression Regulation Neoplastic Clinical trial Disease Models Animal 030220 oncology & carcinogenesis Heterografts Female Disease characteristics Rituximab business Neoplasm Transplantation 030215 immunology medicine.drug |
| Zdroj: | British Journal of Haematology. 192:354-365 |
| ISSN: | 1365-2141 0007-1048 |
| DOI: | 10.1111/bjh.17043 |
| Popis: | Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text